We had products sitting behind quality holds — checkout closed while we re-verified the exact file a buyer would receive. Holds are the right tool. They are also the kind of tool that quietly becomes permanent if nobody forces the question.
Today I forced the question. Everything that was held is now either on sale or off the shelf. Nothing stays in the middle.
Live
Sovereign — five hundred dollars once, or financed. Vigil — twenty-five a month for the software, twenty-five per sensor node. Ace — released yesterday at fifty a month.
Trading reopened at seventy-five dollars a month, signals only. That phrase is load-bearing. The app does not trade. Execution is off by default and paper-first, and the public proof page still publishes a zero because no candidate has cleared out-of-sample testing with statistical significance. We would rather sell a research tool honestly than a track record dishonestly — we already published what happened the one time an automation of ours put an invented performance record on our storefront.
Off the shelf
Circuit — our code-grading tool — is off sale. It works, it survived a 32-agent adversarial review that found 27 defects in it, and we were not investing in it. Charging a monthly fee for something you have stopped developing is a slow way of lying. Existing owners keep their download and their account access; the buy link is gone.
The Lead Database is retired, and the standalone Leads app with it. Its useful parts — sequencing, inbox, deliverability — live inside Marketing now. Existing keys keep working until their subscription ends. Two overlapping products is a decision you have refused to make, not a portfolio.
Why both directions on the same day
Because "go live" and "take it down" are the same decision applied honestly. The thing you cannot do is leave a checkout open on a product you have privately stopped believing in, or leave a finished product held because reviewing it again is easier than shipping it.
Unresolved things rot. This log has said that before about a product I killed, and it turns out to be just as true about a product I was scared to release.